DSpace university logo mark
Advanced Search
Japanese | English 

NAOSITE : Nagasaki University's Academic Output SITE > School of Pharmaceutical Sciences > Articles in academic journal >

Blockade of the ERK or PI3K-Akt signaling pathway enhances the cytotoxicity of histone deacetylase inhibitors in tumor cells resistant to gefitinib or imatinib.


File Description SizeFormat
BBRC_Kohno.pdf2.51 MBAdobe PDFView/Open

Title: Blockade of the ERK or PI3K-Akt signaling pathway enhances the cytotoxicity of histone deacetylase inhibitors in tumor cells resistant to gefitinib or imatinib.
Authors: Ozaki, Kei-Ichi / Kosugi, Masaki / Baba, Nobuyuki / Fujio, Kohsuke / Sakamoto, Toshiaki / Kimura, Shinya / Tanimura, Susumu / Kohno, Michiaki
Issue Date: 22-Jan-2010
Publisher: Elsevier Inc.
Citation: Biochemical and biophysical research communications, 391(4), pp.1610-1615; 2010
Abstract: Deregulated activation of protein tyrosine kinases, such as the epidermal growth factor receptor (EGFR) and Abl, is associated with human cancers including non-small cell lung cancer (NSCLC) and chronic myeloid leukemia (CML). Although inhibitors of such activated kinases have proved to be of therapeutic benefit in individuals with NSCLC or CML, some patients manifest intrinsic or acquired resistance to these drugs. We now show that, whereas blockade of either the extracellular signal-regulated kinase (ERK) pathway or the phosphatidylinositol 3-kinase (PI3K)-Akt pathway alone induced only a low level of cell death, it markedly sensitized NSCLC or CML cells to the induction of apoptosis by histone deacetylase (HDAC) inhibitors. Such enhanced cell death induced by the respective drug combinations was apparent even in NSCLC or CML cells exhibiting resistance to EGFR or Abl tyrosine kinase inhibitors, respectively. Co-administration of a cytostatic signaling pathway inhibitor may contribute to the development of safer anticancer strategies by lowering the required dose of cytotoxic HDAC inhibitors for a variety of cancers.
Keywords: Chronic myeloid leukemia / Drug resistance / HDAC inhibitor / MEK inhibitor / Non-small cell lung cancer / PI3K inhibitor
URI: http://hdl.handle.net/10069/22719
ISSN: 0006291X
DOI: 10.1016/j.bbrc.2009.12.086
PubMed ID: 20026060
Rights: Copyright © 2009 Elsevier Inc. All rights reserved.
Type: Journal Article
Text Version: author
Appears in Collections:Articles in academic journal

Citable URI : http://hdl.handle.net/10069/22719

All items in NAOSITE are protected by copyright, with all rights reserved.

 

Valid XHTML 1.0! Copyright © 2006-2015 Nagasaki University Library - Feedback Powerd by DSpace